Search
Showing results for "clinical trials"
Overview of Health Issues in School-aged Children with Down Syndrome
Siblings of children with disabilities: challenges and opportunities
An exciting opportunity has opened up at ORIGINS.
The PCH Diabetes Clinical team will again be collecting T1DAL surveys between June and July 2024, followed by PAID between November 2024 and January 2025.
Ever wondered what a national committee does? Who can be a member and what they do?
Congratulations to PCH Diabetes who put up a challenge that was selected for the recent WA Health Hackathon Week.
Jack Canning, a PhD researcher in the Wal-yan Respiratory Centre’s Phage WA team, has made a significant finding in the search for alternative treatments to antimicrobial-resistant (AMR) bacteria.
At present, limited literature exists exploring patient preferences for prophylactic treatment of acute rheumatic fever and rheumatic heart disease. Given low treatment completion rates to this treatment in Australia, where the burden of disease predominantly affects Aboriginal and Torres Strait Islander people, an improved understanding of factors driving patient preference is required to improve outcomes.
A future Streptococcus pyogenes (Strep A) vaccine will ideally prevent a significant burden of lower limb cellulitis; however, natural immune responses to proposed vaccine antigens following an episode of cellulitis remain uncharacterized.
The 2023 Australian guideline for assessing and managing cardiovascular disease risk provides updated evidence-based recommendations for the clinical assessment and management of cardiovascular disease (CVD) risk for primary prevention. It includes the new Australian CVD risk calculator based on an equation developed from a large New Zealand cohort study, customised and recalibrated for the Australian population. The new guideline replaces the 2012 guideline that recommended CVD risk assessment using the Framingham risk equation.